Board of directors

• Pr Etienne Baulieu – MD, PhD, President
  • Member of the US and French Academies of Sciences
  • Brought RU486 to the market
  • Deciphered DHEA properties
  • Lasker Award winner and numerous other prestigious awards
  • Brings high-level, lifelong expertise in Neurosteroids
  • Brings outstanding vision of medical development

• Dr Isabelle Villey – PhD, MBA, Chief Executive Officer
  • Former INSERM researcher & vice-director of the Vision Institute
  • Former COO of a start-up company (ophtha device)
  • Brings alliance of business & science

   

• Dr Nicolas Froger – PhD, Head Of Preclinical Research
  • Former group leader at the Vision Institute
  • Brings knowledge and know-how in Neurotraumatology and Depression

---

Board of advisors

International tier-top Scientific Advisors

• Pr Robin FRANKLIN, Neurobiologist,
  Director of the Cambridge Stem Cell Institute, Cambridge University, UK ; 
• Pr Barbara MASON, Neurobiologist,
  Director of the Scripps Alcohol Human Research Laboratory, NIH/USA;
• Pr Philippe FOSSATI, Psychiatrist
  Chief of Psychiatry unit, Depression/Treatment Resistant Depression service, La Salpêtrière Hospital, Paris, France;
• Pr Raphaël GAILLARD, Psychiatrist,
  Chief of Psychiatry unit, Depression/Treatment Resistant Depression/ Addiction service, Ste Anne Hospital, Paris, France.
• Pr Pierre BLIER, Psychiatrist
  Chief of Psychiatric unit, The Royal Hospital, Toronto, Canada;

 

Regulatory and Drug Development

• Dr Denis RAVEL, PhD in metabolism,
  ex-SERVIER, ex-Bayer, >30 years experience in bringing neurocompounds to Phase 3 and licensing